Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec

IMMUNIC, INC.

2024-Q2 EPS reported -$0.51

Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.
Cash $79.7M as of June 30, 2024; expects runway into Q3 2025.
Jason Tardio (ex-Novartis, Biogen) appointed COO and President effective July 12, 2024.
Simona Skerjanec (ex-Roche Neuroscience head) joined Board of Directors July 22, 2024.
Phase 2 CALLIPER top-line data for vidofludimus calcium in PMS expected April 2025; ENSURE Phase 3 RMS trials on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.